This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barchiesi, F. Articles by Graybill, J. R. Search for Related Content PubMed PubMed Citation Articles by Barchiesi, F. Articles by Graybill, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1996, 1317-1320, Vol 40, No. 5
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model

F Barchiesi, LK Najvar, MF Luther, G Scalise, MG Rinaldi and JR Graybill
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7750, USA.

Four strains of Candida albicans, isolated from two patients with AIDS who had undergone prolonged fluconazole therapy for oral candidiasis, were studied in a model of disseminated murine candidiasis. Pre- and posttreatment isolates from each patient were genetically related, and the fluconazole MICs for the strains had increased significantly, from 0.25 to 32 micrograms/ml for the strains isolated from patient 1 and from 1.0 to 16 micrograms/ml for the strains isolated from patient 2. Mice were infected intravenously and were treated orally with fluconazole. For survival studies, mice were treated from day 1 to day 10 postinfection and were observed through day 30. The fluconazole dosages were as follows: 0.25, 0.5, 1.0, and 5.0 mg/kg of body weight twice a day. For tissue burden studies, two groups of mice (each group received fluconazole at 0.25 or 5.0 mg/kg) were treated from day 1 to day 7 and were sacrificed 1 day later for quantitative tissue cultures of the spleen and both kidneys. For pretreatment isolates from both patients, all fluconazole dosing regimens were effective at prolonging survival compared with the survival of the control groups. For posttreatment isolates, only fluconazole at 5.0 mg/kg was effective at prolonging survival. Both fluconazole dosing regimens used in the tissue burden studies significantly reduced the counts of the pretreatment isolate from patient 1 in the spleen and kidney, while fluconazole at 5.0 mg/kg was effective at reducing the counts of the posttreatment isolate. For both isolates from patient 2, only fluconazole at 5.0 mg/kg was effective at reducing the counts in the spleen and kidney. The study indicates that C. albicans mutation to resistance to fluconazole may play a critical role in fluconazole- refractory oral candidiasis in AIDS patients.

This article has been cited by other articles:

• Gauthier, C., Weber, S., Alarco, A.-M., Alqawi, O., Daoud, R., Georges, E., Raymond, M. (2003). Functional Similarities and Differences between Candida albicans Cdr1p and Cdr2p Transporters. Antimicrob. Agents Chemother. 47: 1543-1554 [Abstract] [Full Text]  
• Martinez, A., Aviles, P., Jimenez, E., Caballero, J., Gargallo-Viola, D. (2000). Activities of Sordarins in Experimental Models of Candidiasis, Aspergillosis, and Pneumocystosis. Antimicrob. Agents Chemother. 44: 3389-3394 [Abstract] [Full Text]  
• Lee, S.-C., Fung, C.-P., Huang, J.-S., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L.-C., Shieh, W.-B. (2000). Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe Candida Infections Treated with Fluconazole. Antimicrob. Agents Chemother. 44: 2715-2718 [Abstract] [Full Text]  
• Vargas, K., Messer, S. A., Pfaller, M., Lockhart, S. R., Stapleton, J. T., Hellstein, J., Soll, D. R. (2000). Elevated Phenotypic Switching and Drug Resistance of Candida albicans from Human Immunodeficiency Virus-Positive Individuals prior to First Thrush Episode. J. Clin. Microbiol. 38: 3595-3607 [Abstract] [Full Text]  
• PINA-VAZ, C., SANSONETTY, F., RODRIGUES, A. G., MARTINEZ-DE-OLIVEIRA, J., FONSECA, A. F., MARDH, P.-A. (2000). Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol 49: 831-840 [Abstract] [Full Text]  
• Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., Scalise, G. (2000). Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44: 1578-1584 [Abstract] [Full Text]  
• Walsh, T. J., Gonzalez, C. E., Piscitelli, S., Bacher, J. D., Peter, J., Torres, R., Shetti, D., Katsov, V., Kligys, K., Lyman, C. A. (2000). Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis. J. Clin. Microbiol. 38: 2369-2373 [Abstract] [Full Text]  
• Ellepola, A.N.B., Samaranayake, L.P. (2000). Oral Candidal Infections and Antimycotics. CROBM 11: 172-198 [Abstract] [Full Text]  
• Graybill, J. R., Montalbo, E., Kirkpatrick, W. R., Luther, M. F., Revankar, S. G., Patterson, T. F. (1998). Fluconazole versus Candida albicans: A Complex Relationship. Antimicrob. Agents Chemother. 42: 2938-2942 [Abstract] [Full Text]  
• Odds, F. C., Van Gerven, F., Espinel-Ingroff, A., Bartlett, M. S., Ghannoum, M. A., Lancaster, M. V., Pfaller, M. A., Rex, J. H., Rinaldi, M. G., Walsh, T. J. (1998). Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models. Antimicrob. Agents Chemother. 42: 282-288 [Abstract] [Full Text]